ANTIBODIES AND ANTI-ANTIBODIES TO STEROID HORMONES, AND BREAST CANCER RISK

Antibodies against sex steroid hormones are known to modulate their serum concentration and  inhibit experimental breast cancer (BC). Hence, these effects could be changed by according anti-idiotypic  antibodies. However, relationships between antibodies and anti-idiotypic antibodies and BC in women are still  poorly studied. The aim of this study was to identify possible associations between occurrence of antibodies  against estradiol and progesterone (IgG-Es1and IgG-Pg1) and according antiidiotypic antibodies (IgG-Es2  and IgG-Pg2), and postmenopausal BC.  Eighty-nine  healthy  women  and  273  BC  patients  were  examined.  A  non-competitive  solid  phase  immunoassay for IgG-Es1 and IgG-Pg1 was performed using estradiol and progesterone conjugates with bovin  serum albumin as antigens. Monoclonal antibodies against Es and Pg as antigens have been used for noncompetitive solid phase immunoassay of IgG-Es2 and IgG-Pg2.  Results: absence of both IgG-Es1 and IgG-Pg1 was revealed in 53.9% of healthy donors and 41.0% of  BC patients (p = 0.04; OR = 0.6). Presence of IgG-Es1 without IgG-Pg1, or IgG-Pg1 without IgG-Es1was  detected for, respectively, 15.7% and 20.2% of healthy women, and in 10.3% and 7.7% of BC patients (p > 0.05).  Simultaneous increase of both IgG-Es1 and IgG-Pg1 was revealed in 10.1% of healthy donors and in 41.0%  of BC patients (p < 0.0001; OR = 5.3). Absence of a single antibogy (IgG-Es2 or IgG-Pg2) showed similar  frequency in the groups under study. Simultaneous increase of both IgG-Es2 and IgG-Pg2 was detected in  52.8% of healthy women and 34.8% of BC patients (p = 0.03; OR = 0.4). Conclusion: We have first revealed  an immunostimulating synergistic effect of antibodies against sex steroid hormones and immunoinhibitory  synergistic effect of appropriate anti-idiotypic antibodies upon the postmenopausal breast cancer risk.

breast cancer, antibodies, anti-idiotypic antibodies, estradiol, progesterone, carcinogenesis

1. Глушков А.Н., Поленок Е.Г., Аносова Т.П., Савченко Я.А., Баканова М.Л., Минина В.И., Мун С.А., Ларин С.А., Костянко М.В. Сывороточные антитела к бензо[a]пирену и хромосомные аберрации в лимфоцитах периферической крови у рабочих углеперерабатывающего предприятия // Российский иммунологический журнал, 2011. Т. 5 (14), № 1. С. 39-44. [Glushkov A.N., Polenok E.G., Anosova T.P., Savchenko Ya.A., Bakanova M.L., Minina V.I., Mun S.A., Larin S.A., Kostyanko M.V. Serum antibodies to benzo[a]pyrene and chromosomal aberrations in lymphocytes peripheral blood at the workers of coal processing enterprise. Rossijskiy immunologicheskiy zhurnal = Russian Journal of Immunology, 2011, Vol. 5 (14), no. 1, pp. 39-44. (In Russ.)]

2. Глушков А.Н., Поленок Е.Г., Костянко М.В., Антонов А.В., Вержбицкая Н.Е., Вафин И.А., Рагожина С.Е. Ассоциации сывороточных антител к эстрадиолу с рецепторами эстрогенов в опухоли у больных раком молочной железы // Российский иммунологический журнал, 2016. T. 10 (19), № 2. С. 166-173. [Glushkov A.N., Polenok E.G., Kostyanko M.V., Antonov A.V., Verzhbitskaya N.E., Vafin I.A., Ragozhina S.E. Associations of the serum antibodies to estradiol and the tumor estrogen receptors at the breast cancer patients. Rossijskiy immunologicheskiy zhurnal = Russian Journal of Immunology, 2016, Vol. 10 (19), no. 2, pp. 166-173. (In Russ.)]

3. Глушков А.Н., Поленок Е.Г., Магарилл Ю.А., Аносова Т.П., Антонов А.В., Вержбицкая Н.Е. Антитела к бензо[а]пирену, эстрадиолу и прогестерону у больных раком молочной железы в постменопаузе // Сибирский онкологический журнал, 2016. Т. 15, № 6. С. 28-34. [Glushkov A.N., Polenok E.G., Magarill Yu.A., Anosova T.P., Antonov A.V., Verzhbitskaya N.E. Antibodies to benzo[a]pyrene, estradiol and progesterone in the postmenopausal breast cancer women. Sibirskiy oncologicheskiy zhurnal = Siberian Journal of Oncology, 2016, Vol. 15, no. 6, pp. 28-34. (In Russ.)]

4. Bao T., Prowell T., Stearns V. Chemoprevention of breast cancer: tamoxifen, raloxifene, and beyond. Am. J. Ther., 2006, Vol. 13, no. 4, pp. 337-348.

5. Bourtourault M., Shacoori V., Guerin J., Saiag B., Rault B. Effects of simultaneous active immunization against 17 beta-estradiol and testosterone on pituitary and ovarian activity in rat. Res. Commun. Chem. Pathol. Pharmacol., 1991, Vol. 72, no. 3, pp. 273-284.

6. Caldwell B.V., Tillson S.A., Esber H., Thorneycroft I.H. Survival of tumors after immunization against estrogens. Nature, 1971, Vol. 231, no. 14, pp. 118-119.

7. Chaudhri R.A., Olivares-Navarrete R., Cuenca N., Hadadi A., Boyan B.D., Schwartz Z. Membrane estrogen signaling enhances tumorigenesis and metastatic potential of breast cancer cells via estrogen receptor-α36 (ERα36). J. Biol. Chem., 2012, Vol. 287, no. 10, pp. 7169-7181.

8. Fortunati N., Catalano M.G., Boccuzzi G., Frairia R. Sex Hormone-Binding Globulin (SHBG), estradiol and breast cancer. Mol. Cell. Endocrinol., 2010, Vol. 316, no. 1, pp. 86-92.

9. Glushkov A., Polenok E., Kostyanko M., Antonov A., Verzhbitskaya N., Vafin I., Ragozhina S. Postmenopausal breast cancer risk in relation to antibodies specific to benzo[a]pyrene, estradiol and progesterone. Iran. J. Cancer Prev., 2016, Vol. 9 (2), e4212. doi: 10.17795/ijcp-4212.

10. Hajian-Tilaki K. Receiver Operating Characteristic (ROC) Curve Analysis for Medical Diagnostic Test Evaluation. Caspian J. Intern. Med., 2013, Vol. 4, no. 2, pp. 627-635.

11. Hillier S.G., Groom G.V., Boyns A.R., Cameron E.H. Effects of active immunisation against steroids upon circulating hormone concentrations. J. Steroid Biochem., 1975, Vol. 6, no. 3-4, pp. 529-535.

12. LaCroix A.Z., Powles T., Osborne C.K., Wolter K., Thompson J.R., Thompson D.D., Allred D.C., Armstrong R., Cummings S.R., Eastell R., Ensrud K.E., Goss P., Lee A., Neven P., Reid D.M., Curto M., Vukicevic S., PEARL Investigators. Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J. Natl. Cancer Inst., 2010, Vol. 102, no. 22, pp. 1706-1715.

13. Luconi M., Francavilla F., Porazzi I., Macerola B., Forti G., Baldi F. Human spermatozoa as a model for studying membrane receptors mediating rapid non-genomic effects of progesterone and estrogens. Steroids, 2004, Vol. 69, no. 8-9, pp. 553-559.

14. Manjer J., Johansson R., Berglund G., Janzon L., Kaaks R., Agren A., Lenner P. Postmenopausal breast cancer risk in relation to sex steroid hormones, prolactin and SHBG (Sweden). Cancer Causes Control, 2003, Vol. 14, no. 7, pp. 599-607.

15. Naik S.L.D., Hedau S., Bahadur A.K., Saha R., Kaur S., Ray A. Sex hormone binding globulin in breast cancer. Indian J. Clin. Biochem., 2008, Vol. 23, no. 3, pp. 250-254.

16. Rawlings N.C., Kennedy S.W., Henricks D.M. The active immunization of the cyclic ewe against an estrone protein conjugate. Theriogenology, 1979, Vol. 12, no. 3, pp. 139-151.

17. Schwartz U., Dyrenfurth I., Khalaf S., Vande Wiele R.L., Ferin M. A comparison of the effects of active immunization of female rhesus monkeys to estradiol-17 or progesterone-20-protein conjugates. J. Steroid Biochem., 1975, Vol. 6, no. 3-4, pp. 541-545.

18. Sestak I. Preventative therapies for healthy women at high risk of breast cancer. Cancer Manag. Res., 2014, Vol. 6, pp. 423-430

19. Somjen D., Kohen F., Lieberherr M. Nongenomic Effects of an anti-idiotypic antibody as an estrogen mimetic in female human and rat osteoblasts. J. Cell. Biochem., 1997, Vol. 65, no. 1, pp. 53-66.

20. Sundaram K., Tsong Y.Y., Hood W., Brinson A. Effect of immunization with estrone-protein conjugate in rhesus monkeys. Endocrinology, 1973, Vol. 93, no. 4, pp. 843-847.

21. Vogel V.G. Role of hormones in cancer prevention. Am. Soc. Clin. Oncol. Educ. Book, 2014, pp. 34-40.

22. Zeleniuch-Jacguotte A., Shore R.E., Koenig K.L., Akhmedkhanov A., Afanasyeva Y., Kato I., Kim M.Y., Rinaldi S., Kaaks R., Toniolo P. Postmenopausal levels of estrogen, androgen and SHBG and breast cancer: longterm results of a prospective study. Brit. J. Cancer, 2004, Vol. 90, no. 1, pp. 153-159.